跳至主要内容
临床试验/jRCT1042250205
jRCT1042250205招募中不适用

A multicenter randomized controlled trial of continuous abdominal wall closure using barbed sutures in abdominal open surgery. (CCOG2601)

未提供0 个研究点目标入组 230 人开始时间: 待定
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
230

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized

入排标准

年龄范围
18age old over 至 No limit(—)
性别
All

入选标准

  • Scheduled to undergo open surgery via an upper midline abdominal incision.
  • ECOG Performance Status (PS) of 0-
  • Age >= 18 years.
  • Body mass index (BMI) <= 35 kg/m
  • Adequate function of major organs (bone marrow, liver, kidney, lung, etc.), meeting all of the following:
  • A) White blood cell count: >= 2500/mm3 and <= 14000/mm3
  • B) Hemoglobin: >= 9.0 g/dL
  • C) Platelet count: >= 100000/mm3
  • D) Total bilirubin: <= 2.0 mg/dL
  • E) Creatinine: <= 2.0 mg/dL
  • Expected to survive for at least 1 year after surgery.
  • Has sufficient decision-making capacity to understand the study and has provided written informed consent personally.

排除标准

  • Patients scheduled to undergo laparoscopic surgery or robot-assisted surgery.
  • Patients undergoing laparotomy via an approach other than a midline incision.
  • Patients expected to have an incision length > 40 cm.
  • Patients with a history of upper abdominal surgery performed via laparotomy.
  • Patients undergoing emergency surgery.
  • Patients who are considered likely to require arterial reconstruction (e.g., superior mesenteric artery, common hepatic artery, celiac artery).
  • Patients with severe ischemic heart disease.
  • Patients with liver cirrhosis or active hepatitis.
  • Patients with chronic respiratory disease requiring treatment (e.g., interstitial pneumonia, pulmonary fibrosis, COPD).
  • Patients on hemodialysis for chronic renal failure.
  • Patients receiving continuous systemic corticosteroids and/or immunosuppressants.
  • Patients with severe drug allergies.
  • Patients with psychotic disorders or psychiatric symptoms deemed to make study participation difficult.
  • Patients with drug or alcohol dependence.
  • Patients judged by the investigator to be inappropriate for participation in this trial.

研究者

发起方
未提供

相似试验

招募中
1 期
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT
2024-519010-31-00Fondazione Melanoma Onlus80
招募中
不适用
Comparison of anesthetic concentration and volume for pain relief after wisdom tooth extraction (OPTIMAL Study)Impacted wisdom tooth
jRCT103125059660
招募中
不适用
A Phase I/II exploratory clinical trial to evaluate the efficacy and safety of RBBM-S1 in patients requiring lumbar interbody fusion for degenerative lumbar disease, in comparison with the standard treatment of autologous bone grafting.lumbar stenosis, spondylolisthesis, spondylolysis, scoliosis, instability, disc disease
jRCT203125056936
招募中
不适用
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (LAURITE 2)Moderate to Severe Glabellar Lines
jRCT2031250845138
已完成
4 期
A pivotal, randomized, open-label, two-treatment, two-sequence, four periods, crossover clinical trial to evaluate the bioequivalence of single doses of Test product Sacubitril/Valsartan, film-coated tablets 97 mg/103 mg (Manufacturer: JSC «Farmak», Ukraine) and Reference Entresto®, film-coated tablets 97 mg/103 mg (Novartis Europharm Limited, Ireland) in healthy subjects under fasted conditions
2023-509484-24-00Farmak JSC36